COVID-19 pandemic, caused by SARS-CoV-2 virus, is threatening lives globally
Immunocompromised individuals, such as those with cancer, are especially at risk
Antibody therapy is a proven method for immediate protections for the immunocompromised or the seriously ill
Accelerate antibody discovery process using single cell proteogenomics
Comprehensive screening to select antibody with the broadest coverage
Able to include samples with different geographical and ethnical background
Proteona Antibody Protection GmbH (PAP) is a biomedical company operating at the forefront of the fight against COVID-19 using single cell sequencing technology to discover neutralizing antibodies. Proteona’s vision is to accelerate treatment development for the most vulnerable, immunocompromised patients.
We do this by utilizing our own single cell technologies to identify the best candidate antibodies and then moving those antibodies through functional testing toward the clinic by tapping on the individual strengths of a team of the top international companies and research institutes in the world who have agreed to form an alliance for the purpose of fighting COVID-19.
Proteona Antibody Protection GmbH was established in 2020 in response to the dire need of immunocompromised individuals, such as those with blood cancer, for a targeted treatment against COVID-19. Its parent company, Proteona, is already active in Singapore and Germany, where it provides single-cell multi-omics data for researchers, clinicians and pharma companies for drug discovery and for treatment optimization for blood cancer patients.